A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial
A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial. // Annals of Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0923753426008872?dgcid=rss_sd_all
A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial. Annals of Oncology. https://www.sciencedirect.com/science/article/pii/S0923753426008872?dgcid=rss_sd_all
“A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial.” Annals of Oncology.
@article{article88415,
title = {A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial},
journal = {Annals of Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0923753426008872?dgcid=rss_sd_all}
}